Navigating Intellectual Property in the Global Economy

Every time you buy a branded medicine, stream a song, or use patented software, international intellectual property law is at work in the background. But how did the world agree on a common framework for protecting these rights? The answer lies in decades of negotiation, political tension between the Global North and Global South, and the eventual emergence of a trade-centred legal architecture that continues to shape economic relationships between nations. For law students in India, understanding this architecture is not just academic-India has been an active, often contentious, participant in shaping it.

Why intellectual property became a global economic issue 🔗

Intellectual property rights (IPR) were originally territorial. Each country set its own rules-how long a patent lasted, what counted as a copyrightable work, how trademarks were protected. This worked reasonably well when most trade was in physical goods. But as technology, pharmaceuticals, software, and creative industries began driving global commerce, the gaps between national IP systems became economic problems. A drug company that spent billions developing a medicine could see generic versions manufactured freely in countries with weak patent laws. A software firm had no reliable way to stop unauthorized copying in markets where copyright enforcement barely existed.

As the WTO notes, the variation in IP protection across the world became a source of genuine tension in international economic relations by the late twentieth century. New rules were needed-not just as a matter of fairness, but to make global trade predictable.

The New International Economic Order: the developing world’s challenge 🔗

Before the current IP framework took shape, a radically different vision was on the table. In 1974, the United Nations General Assembly adopted the Declaration on the Establishment of a New International Economic Order (NIEO), driven primarily by the Group of 77 (G77) developing nations and the Non-Aligned Movement. India was among the central voices in this movement.

The NIEO was premised on a straightforward argument: the existing international economic system was built when most developing nations were still colonized, and it continued to serve the interests of wealthy industrialized countries at the expense of the newly independent Global South. The NIEO called for a fundamental restructuring-fairer trade terms, sovereignty over natural resources, regulation of multinational corporations, and critically, free or subsidized transfer of technology from developed to developing nations.

On intellectual property specifically, the NIEO demanded the transfer of technology to the Third World rather than allowing wealthy nations to “hoard” it behind patent walls. The argument was that IP protections, as they existed, were a mechanism for maintaining technological dependency. Countries like India and Brazil argued that the global IP order functioned as a new form of economic colonialism-securing monopoly rents for corporations based in the US and Europe while blocking industrialization elsewhere.

The NIEO ultimately failed to achieve its goals. Developed nations, led by the United States, resisted its proposals. By the early 1980s, the political momentum had shifted decisively toward market liberalization and stronger, not weaker, IP protection. The NIEO gave way to a very different settlement-one anchored in trade law rather than development policy.

From GATT to WTO: linking IP to international trade 🔗

The pivotal shift came during the Uruguay Round of the General Agreement on Tariffs and Trade (GATT), which ran from 1986 to 1994. For the first time, intellectual property was formally brought into the multilateral trading system. The United States, in particular, pushed aggressively for this linkage-driven in large part by lobbying from major pharmaceutical and technology corporations who wanted enforceable global IP standards rather than a patchwork of national laws.

The strategy was effective. By tying IP standards to market access and trade concessions, developed countries created powerful incentives for developing nations to comply. Countries that wanted access to rich-country markets had to accept a new global IP regime as part of the deal. As Wikipedia’s account of the TRIPS Agreement notes, campaigns combining economic incentives under the Generalized System of Preferences with pressure under Section 301 of the US Trade Act played a significant role in overcoming resistance from countries like India, Brazil, and Thailand.

The result of the Uruguay Round was the establishment of the World Trade Organization (WTO) in 1995, replacing GATT. The WTO brought together rules on goods, services, and, for the first time, intellectual property-under one institutional roof with a binding dispute settlement mechanism.

The TRIPS Agreement: the cornerstone of global IP law 🔗

Annexed to the WTO Agreement as Annex 1C, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into force on 1 January 1995. It is the most comprehensive multilateral agreement on intellectual property ever concluded, binding all 164 WTO member nations.

TRIPS establishes minimum standards for the protection and enforcement of a wide range of intellectual property rights, including copyrights, patents, trademarks, geographical indications, industrial designs, and trade secrets. The key word is “minimum”-member countries can provide stronger protection if they wish, but they cannot fall below the TRIPS floor.

What TRIPS requires 🔗

Under TRIPS, member countries must incorporate the core obligations of earlier international conventions-particularly the Paris Convention for industrial property and the Berne Convention for copyright-into their domestic legal systems. Beyond that, TRIPS adds new requirements. Patents must be available in all fields of technology for a minimum of twenty years. Copyright protection must extend for at least fifty years after the author’s death. Trademarks must be protected for at least seven years, renewable indefinitely.

Crucially, TRIPS does not just set standards-it mandates enforcement. Member countries must provide civil and criminal remedies for IP infringement, border measures to stop counterfeit goods, and access to the WTO’s dispute settlement mechanism for resolving cross-border IP disputes. This enforcement dimension was something earlier IP conventions, administered through the World Intellectual Property Organization (WIPO), had conspicuously lacked.

The stated objectives: balancing innovation with access 🔗

TRIPS is not simply a document that protects rights holders. Its preamble and Article 7 spell out that IP protection should contribute to technological innovation, the transfer and dissemination of technology, and should serve the mutual advantage of producers and users of knowledge-in a manner conducive to social and economic welfare. This language matters: it has provided the legal basis for developing countries to argue for flexibilities that balance IP protection against public interest concerns.

The tension at the heart of the system: long-term benefits vs. short-term costs 🔗

The TRIPS framework rests on a specific economic theory: strong IP protection incentivizes investment in research, development, and creativity. If innovators can recover their costs through exclusive rights, they will produce more innovations-and this benefits everyone in the long run. The argument is most compelling for pharmaceuticals, where the cost of developing a new drug can run into billions of dollars.

But this long-term logic comes with real short-term costs, and these fall disproportionately on developing countries. When pharmaceutical patents prevent the production of cheap generics, patients in low-income countries cannot afford life-saving medicines. When copyright terms extend for decades, educational materials become expensive. When agricultural patents restrict seed-saving, small farmers face new constraints.

For India, these tensions are not abstract. India’s generic pharmaceutical industry had, for decades, supplied affordable medicines across the developing world. Indian patent law before 2005 did not recognize product patents for pharmaceuticals-only process patents. This meant Indian companies could legally produce generic versions of patented medicines using different manufacturing processes. TRIPS required India to overhaul this framework. When India amended the Patents Act in 2005 to comply with TRIPS, Section 3(d) was inserted as a safeguard-preventing the grant of patents for minor modifications of known drugs unless they showed significantly enhanced efficacy. This provision has been internationally significant and controversial.

The Doha Declaration: pushing back through the system 🔗

The backlash from developing countries did not take the form of rejecting TRIPS outright. Instead, they pushed for an authoritative interpretation of the flexibilities already within the agreement. This culminated in the 2001 Doha Declaration on the TRIPS Agreement and Public Health, adopted at the WTO’s Fourth Ministerial Conference in Qatar.

The Doha Declaration made several things explicit. It confirmed that TRIPS does not and should not prevent members from taking measures to protect public health. It affirmed the right of members to use TRIPS flexibilities-including compulsory licensing-to promote access to medicines. It clarified that each country has the right to determine what constitutes a national emergency justifying compulsory licensing, and that public health crises such as HIV/AIDS, tuberculosis, and malaria qualify.

A compulsory licence allows a government to authorize a third party to produce a patented product without the patent holder’s consent, in exchange for adequate remuneration. India’s first-and so far only-compulsory licence was issued in 2012, for Bayer’s cancer drug Nexavar, making it available at a fraction of the original price. The decision attracted significant pressure from the US government, illustrating precisely the political dynamics the NIEO had sought to address decades earlier.

The Doha Declaration also addressed a structural gap: WTO rules originally required that compulsory licences be predominantly for domestic supply. Countries without pharmaceutical manufacturing capacity could not benefit. This was resolved through a 2005 amendment to TRIPS (which entered into force in 2017), inserting Article 31bis, which allows compulsory licences specifically for export to countries that cannot manufacture medicines domestically.

Global IP harmonization: what it means in practice 🔗

The TRIPS framework represents a significant move toward global IP harmonization-the alignment of national IP laws around common minimum standards. For businesses operating across borders, this predictability is valuable. A patent granted in India, Germany, or Brazil now comes with a baseline set of guarantees and enforcement tools that were unavailable before 1995.

But harmonization is not uniformity, and this distinction matters. TRIPS sets floors, not ceilings, and it builds in flexibility for countries to adapt standards to their development contexts. The challenge in practice is that these flexibilities are often difficult to exercise. Political pressure from major trading partners, complexity in domestic implementation, and the risk of trade sanctions under bilateral agreements have all deterred developing countries from fully utilizing the space TRIPS formally allows.

Nobel laureate economist Joseph Stiglitz has argued that the TRIPS regime, as it evolved, was not even in the long-term interest of developed countries-let alone developing ones-because it prioritized monopoly rents over dynamic innovation and broad access to knowledge. This critique has become more prominent as debates over access to COVID-19 vaccines brought IP politics back to the center of global attention. India and South Africa jointly proposed a waiver of certain TRIPS provisions during the pandemic, reflecting the continuity of tensions that trace back to the NIEO era.

India’s position in the global IP order 🔗

India’s relationship with the international IP system has always been strategically calibrated. As a leader of the Non-Aligned Movement, India championed the NIEO and advocated for technology transfer. As a participant in the Uruguay Round, India resisted but ultimately accepted TRIPS, securing some key flexibilities in the process. As a major generic pharmaceutical producer, India has a direct economic stake in how patents are interpreted and how compulsory licensing provisions are applied.

Today, India sits at an interesting intersection. Its domestic IP laws must comply with TRIPS, but the Patents Act’s Section 3(d) continues to be cited internationally as a model for preventing “evergreening”-the practice of securing extended patent protection through trivial modifications. India’s approach illustrates that even within the TRIPS framework, there is meaningful room for countries to define their own IP policy-if they have the political will and legal sophistication to do so.

Understanding the international IP order means understanding this tension: between a framework designed to produce long-term innovation benefits for the world and the short-term costs that framework imposes on the countries least able to absorb them. The NIEO asked for redistribution; TRIPS delivered harmonization. Whether those two goals can ultimately be reconciled-through Doha-style flexibilities, technology transfer commitments, or new institutional arrangements-remains one of the central questions of international economic law.

What do you think? Given that TRIPS was designed to set minimum standards while allowing countries flexibility for public interest measures, why do you think developing countries like India have found it politically difficult to fully exercise these flexibilities in practice? And if a new international economic order were negotiated today, what would a truly balanced global IP framework look like for countries at different stages of development?

References

1. https://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm
2. https://en.wikipedia.org/wiki/New_International_Economic_Order
3. https://progressive.international/blueprint/1350647f-15c9-4f62-8b39-bddadc7046c3-the-new-international-economic-order/en/
4. https://en.wikipedia.org/wiki/TRIPS_Agreement
5. https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
6. https://www.wto.org/english/docs_e/legal_e/trips_e.htm
7. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
8. https://www.wto.org/english/tratop_e/trips_e/pharmpatent_e.htm
9. https://orfonline.org/research/the-trips-agreement-and-public-health